Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor α, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study

Metabolism: Clinical and Experimental

Volumn 58, Issue 3, 2009, Pages 283-289

  Do, Hong Quang ^a   Nazih, Hassan ^a   Luc, Gérald ^b   Arveiler, Dominique ^c   Ferrières, Jean ^d   Evans, Alun ^e   Amouyel, Philippe ^b   Cambien, François ^f   Ducimetière, Pierre ^g   Bard, Jean Marie ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d INSERM   (France)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 59849128251     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.09.026     Document Type: Article

References (29)

1. Wilson P.W.F. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol 66 (1990) 7A-10A
2. Couillard C., Bergeron J., Despres J.P., Gagnon J., Rankinen T., Leon A.S., et al. Apolipoprotein AI- and AI:AII-containing lipoproteins in white men and women of the HERITAGE Family study: associations with metabolic risk profile variables. Metabolism 52 (2003) 1530-1536
3. Dauchet L., Ferrieres J., Arveiler D., Yarnell J.W., Gey F., Ducimetiere P., et al. Frequency of fruit and vegetable consumption and coronary heart disease in France and North Ireland: the PRIME study. Br J Nutr 92 (2004) 963-972
4. Ruaño G., Seip R.L., Windemuth A., et al. Apolipoprotein A1 genotype affects change in high density lipoprotein cholesterol subfractions with exercise training. Atherosclerosis 185 (2005) 65-69
5. Marques-Vidal P., Montaye M., Arveiler D., Evans A., Bingham A., Ruidavets J.B., et al. Alcohol consumption and cardiovascular disease: differential effects in France and Northern Ireland. The PRIME study. Eur J Cardiovasc Prev Rehabil 11 (2004) 336-343
6. Yarnell J., Yu S., Patterson C., Cambien F., Arveiler D., Amouyel P., et al. Family history, longevity, and risk of coronary heart disease: the PRIME study. Int J Epidemiol 32 (2003) 71-77
7. Manresa J.M., Zamora A., Tomas M., Senti M., Fito M., Covas M.I., et al. Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. Eur J Cardiovasc Prev Rehabil 13 (2006) 738-744
8. Davignon J., Gregg R.E., and Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8 (1988) 1-21
9. Nassar B.A., Rockwood K., Kirland S.A., et al. Improved prediction of early-onset coronary artery disease using APOE e{open}4, BChE-K, PPARγ2 Pro12 and ENOS T-786C in a polygenic model. Clinical Biochemistry 39 (2006) 109-114
10. Tai E.S., Demissie S., Cupples L.A., Corella D., et al. Association between the PPARA L162V polymorphism and plasma lipid level: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 22 (2002) 805-810
11. Yamakawa-Kobayashi K., Ishiguro H., Arinami T., Miyazaki R., and Hamaguchi H. A Val227Ala polymorphism in the peroxisome proliferator activated receptor α (PPARα) gene is associated with variations in serum lipid levels. J Med Genet 39 (2002) 189-191
12. Zheng K., Zhang S., Zhang L., He Y., et al. Carriers of three polymorphisms of cholesteryl ester transfer protein gene are at increased risk to coronary heart disease in Chinese population. Int J Cardiol 103 (2005) 259-265
13. Agerholm-Larsen B., Tybjaerg-Hansen A., Schnohr P., Steffensen R., and Nordestgaard B.G. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation 102 (2000) 2197-2203
14. Ducimetiere P., Ruidavets J.B., Montaye M., Haas B., and Yarnell J. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol 30 (2001) 1057-1062
15. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1989) 1215
16. Parra H.J., Mezdour H., Ghalim N., Bard J.M., and Fruchart J.C. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 36 (1990) 1431-1435
17. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
18. Lloyd D.B., Lira M.E., Wood L.S., Durham L.K., et al. Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by Torcetrapib. J Biol Chem 280 (2005) 14918-14922
19. Arai H., Yamamoto A., Matsuzawa Y., Saito Y., Yamada N., Oikawa S., et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in general Japanese population in 2000. J Atheroscler Thromb 12 (2005) 240-250
20. Blankenberg S., Tiret L., Bickel C., Schlitt A., Jungmair W., Genth-zotz S., et al. Genetic variation of the cholesterol ester transfer protein gene and the prevalence of coronary artery disease. The AtheroGene case control study. Z Kardiol 93 Suppl 4 (2004) IV16-IV23
21. Ordovas J.M., Corella D., Cupples L.A., et al. Polyunsaturated fatty acids modulate effects of the APOA1G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner : the Framingham Study. Am J Clin Nutr 75 (2002) 38-46
22. Jeenah M., Kessling A., Miller N., and Humphries S.E. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 7 (1990) 233-241
23. Pagani F., Sidoli A., Giudici G.A., Barenghi L., Vergani C., and Baralle F.E. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 31 (1990) 1371-1377
24. Pitsavos C., Choumerianou D.M., Skoumas J., Maumus S., et al. Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clin Exp Med 5 (2005) 196-201
25. Camsari A., Tamer L., Aras Ates N., Pekdemir H., et al. Apolipoprotein E polymorphism in diabetic and non-diabetic patients: does it really contribute to atherosclerosis?. Acta Cardiol 60 (2005) 409-414
26. Khan Q.D., Pontefract D.E., Lyengar S., and Ye S. Evidence of differing genotypic effects of PPARα in women and men. J Med Genet 41 (2004) e79
27. Vohl M.C., Lepage P., Gaudet D., Brewer C.G., et al. Molecular scanning of the human PPARα gene: association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res 41 (2000) 945-952
28. Tai E.S., Corella D., Demissie S., Cupples L.A., et al. Polyunsaturated fatty acids interact with the PPARA-L162 polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 135 (2005) 397-403
29. Tai E.S., Collins D., Robins S.J., O'Connor Jr. J.J., Bloomfield H.E., Ordovas J.M., et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187 (2006) 153-160